/Biogen%20Inc%20logo%20on%20HQ-by%20Tada%20Images%20via%20Shutterstock.jpg)
Cambridge, Massachusetts-based Biogen Inc. (BIIB) is a biotechnology company that discovers, develops, and delivers innovative therapies for serious neurological and neurodegenerative diseases. It is valued at a market cap of $27.7 billion.
Companies worth $10 billion or more are typically classified as “large-cap stocks,” and Biogen fits the label perfectly, with its market cap exceeding this threshold, underscoring its size, influence, and dominance within the drug manufacturers - general industry. Beyond its core neurology focus, the company is actively expanding its pipeline across immunology and rare diseases, leveraging cutting-edge modalities like antisense oligonucleotides (ASOs) to address high unmet medical needs.